Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)
口服 NLRP3 炎症小体抑制剂 ZYIL1 的安全性、耐受性、药代动力学和药效学：首次人体 1 期研究（单次递增剂量和多次递增剂量）
期刊:Clinical Pharmacology in Drug Development
影响因子:1.8
doi:10.1002/cpdd.1162
Parmar, Deven V; Kansagra, Kevinkumar A; Momin, Taufik; Patel, Hardik B; Jansari, Gaurav A; Bhavsar, Jay; Shah, Chintan; Patel, Jayesh M; Ghoghari, Ashok; Barot, Ajay; Sharma, Bhavesh; Viswanathan, Kasinath; Patel, Harilal V; Jain, Mukul R
炎症
炎症/感染
LRP3
Human
NLRP3
炎性小体
免疫/内分泌
